Literature DB >> 34250403

Synchronous, Yet Genomically Distinct, GIST Offer New Insights Into Precise Targeting of Tumor Driver Mutations.

Eleftherios A Makris1,2, Ashwyn K Sharma1,2, Erik N Bergstrom3,4, Xiaojun Xu2,5, Jorge de la Torre1,2, Sudeep Banerjee2,6, Vi Nguyen1,2, Mojgan Hosseini7, Adam Burgoyne2,8, Olivier Harismendy2,5, Ludmil B Alexandrov2,3,4, Jason K Sicklick1,2.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 34250403      PMCID： PMC8232556          DOI： 10.1200/PO.20.00384

Source DB:  PubMed          Journal:  JCO Precis Oncol        ISSN： 2473-4284


× No keyword cloud information.
  29 in total

Review 1.  Current management of succinate dehydrogenase-deficient gastrointestinal stromal tumors.

Authors:  Pushpa Neppala; Sudeep Banerjee; Paul T Fanta; Mayra Yerba; Kevin A Porras; Adam M Burgoyne; Jason K Sicklick
Journal:  Cancer Metastasis Rev       Date:  2019-09       Impact factor: 9.264

2.  Gastrointestinal stromal tumors, version 2.2014.

Authors:  Margaret von Mehren; R Lor Randall; Robert S Benjamin; Sarah Boles; Marilyn M Bui; Ephraim S Casper; Ernest U Conrad; Thomas F DeLaney; Kristen N Ganjoo; Suzanne George; Ricardo J Gonzalez; Martin J Heslin; John M Kane; Joel Mayerson; Sean V McGarry; Christian Meyer; Richard J O'Donnell; Alberto S Pappo; I Benjamin Paz; John D Pfeifer; Richard F Riedel; Scott Schuetze; Karen D Schupak; Herbert S Schwartz; Brian A Van Tine; Jeffrey D Wayne; Mary Anne Bergman; Hema Sundar
Journal:  J Natl Compr Canc Netw       Date:  2014-06       Impact factor: 11.908

3.  Epidemiology of gastrointestinal stromal tumors in the era of histology codes: results of a population-based study.

Authors:  Grace L Ma; James D Murphy; Maria E Martinez; Jason K Sicklick
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-10-02       Impact factor: 4.254

4.  Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors.

Authors:  Narasimhan P Agaram; Grace C Wong; Tianhua Guo; Robert G Maki; Samuel Singer; Ronald P Dematteo; Peter Besmer; Cristina R Antonescu
Journal:  Genes Chromosomes Cancer       Date:  2008-10       Impact factor: 5.006

5.  Population-Based Epidemiology and Mortality of Small Malignant Gastrointestinal Stromal Tumors in the USA.

Authors:  Taylor M Coe; Katherine E Fero; Paul T Fanta; Robert J Mallory; Chih-Min Tang; James D Murphy; Jason K Sicklick
Journal:  J Gastrointest Surg       Date:  2016-03-29       Impact factor: 3.452

Review 6.  "Wild type" GIST: Clinicopathological features and clinical practice.

Authors:  Ryuichi Wada; Hiroki Arai; Shoko Kure; Wei-Xia Peng; Zenya Naito
Journal:  Pathol Int       Date:  2016-07-18       Impact factor: 2.534

Review 7.  Targeted therapy and personalized medicine in gastrointestinal stromal tumors: drug resistance, mechanisms, and treatment strategies.

Authors:  George Z Li; Chandrajit P Raut
Journal:  Onco Targets Ther       Date:  2019-07-01       Impact factor: 4.147

8.  Pan-cancer whole-genome analyses of metastatic solid tumours.

Authors:  Peter Priestley; Jonathan Baber; Martijn P Lolkema; Neeltje Steeghs; Ewart de Bruijn; Charles Shale; Korneel Duyvesteyn; Susan Haidari; Arne van Hoeck; Wendy Onstenk; Paul Roepman; Mircea Voda; Haiko J Bloemendal; Vivianne C G Tjan-Heijnen; Carla M L van Herpen; Mariette Labots; Petronella O Witteveen; Egbert F Smit; Stefan Sleijfer; Emile E Voest; Edwin Cuppen
Journal:  Nature       Date:  2019-10-23       Impact factor: 49.962

9.  Duodenal-Jejunal Flexure GI Stromal Tumor Frequently Heralds Somatic NF1 and Notch Pathway Mutations.

Authors:  Adam M Burgoyne; Martina De Siena; Maha Alkhuziem; Chih-Min Tang; Benjamin Medina; Paul T Fanta; Martin G Belinsky; Margaret von Mehren; John A Thorson; Lisa Madlensky; Timothy Bowler; Francesco D'Angelo; Dwayne G Stupack; Olivier Harismendy; Ronald P DeMatteo; Jason K Sicklick
Journal:  JCO Precis Oncol       Date:  2017-08-15

10.  BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance.

Authors:  G S Falchook; J C Trent; M C Heinrich; C Beadling; J Patterson; C C Bastida; S C Blackman; R Kurzrock
Journal:  Oncotarget       Date:  2013-02
View more
  1 in total

1.  Patient demographics, clinicopathologic features, and outcomes in wild-type gastrointestinal stromal tumor: a national cohort analysis.

Authors:  Tahsin M Khan; Emily A Verbus; Alexander J Rossi; Jonathan M Hernandez; Jeremy L Davis; Brian A Coakley; Andrew M Blakely
Journal:  Sci Rep       Date:  2022-04-06       Impact factor: 4.996
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.